ABSTRACT
Background and aims Patients with chronic hepatitis C infection have high rates of major depressive disorder. The reasons for this are multifactorial, but social and demographic factors do not entirely explain the increased burden. Direct neuropathologic effect of the virus in the development of depression has been postulated but the mechanisms remain unclear. Single nucleotide polymorphisms (SNPs) in FKBP5 (protein product FKBP51), a co-chaperone of the glucocorticosteroid receptor, have been associated with greater severity of affective disorders. We examined the interaction between FKBP5 SNPs and chronic hepatitis C infection in patients with and without depressive symptoms.
Methods forty-one subjects completed quality of life and psychiatric questionnaires. Thirteen patients were classified as depressed on the Hospital Anxiety and Depression Scale depression sub-score (HADS-D ≥11). FKBP51 protein expression, FKBP5 mRNA and FKBP5 SNP analysis was compared between those with and without depression.
Results There were no statistically significant differences between the groups in demographics, medical co-morbidities or substance use. A moderate negative correlation (Spearman rho -0.53, p<0.001) was found between HADS-D sub-score and FKBP51 protein levels in serum. Correspondingly, the average expression fold change in peripheral blood FKBP5 mRNA relative to a reference gene was lower in the depressed group at 0.76 compared to controls at 1.40. There was no differential expression of FKBP5 SNPs between the groups.
Conclusion Levels of FKBP5 mRNA and FKBP51 are lower in hepatitis C patients with depression and further exploration of this interaction is required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by MSD for the laboratory work only. No authors received any payment or funding.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures This work was funded by an unrestricted grant from Merck Sharp and Dohme; however, they had no input into study design, analysis of results, manuscript drafting or approval of final draft. This unrestricted grant covered laboratory supplies but not salaries or honoraria.
Data Availability
Data is available from the authors. There is no external database
Abbreviations
- ACTH
- Adrenocorticotropic hormone BMI Body mass index
- CHC
- Chronic hepatitis C
- CRH
- corticotropin releasing hormone
- DNA
- Deoxyribonucleic acid
- GR
- Glucocorticosteroid receptor
- HADS-A
- Hospital Anxiety and Depression Scale anxiety sub-score
- HADS-D
- Hospital Anxiety and Depression Scale depression sub-score
- HRQoL
- Health-related quality of life
- HIV
- Human Immunodeficiency Virus
- HPAA
- Hypothalamic-pituitary-adrenal axis
- MCS
- Mental Component Summary
- mRNA
- Messenger ribonucleic acid
- MFIS
- Modified Fatigue Impact Scale
- PCS
- Physical Component Summary
- SD
- Standard deviation
- SF-36
- Short Form-36 quality of life questionnaire scale
- SNP
- Single nucleotide polymorphisms